Advances in
Bone Cancer Treatment:
Preventing Metastasis and Bone Loss
CME Information
Up to 3.0 AMA PRA Category 1 Credit(s)™
Release date: February 2010 Valid through: February 2011
Course Material: Online Only
Receiving CME Credit
To receive online CME credit for this activity, read the full activity then click below to complete the post-test and evaluation hosted on freeCME.com. You will be able to print your CME certificate immediately following completion of the post-test and evaluation.
Target Audience
This educational activity is intended for oncologists, urologists, and other medical professionals who assess, treat, or counsel cancer patients.
Learning Objectives
After completing this activity, the participant will be able to:
- Discuss and assess appropriate use of bone-targeted agents to treat bone metastasis and its complications in cancer patients.
- Discuss and assess current data on potential role of bone- targeted agents in preventing bone metastasis.
- Discuss and assess appropriate use of bone-targeted agents to prevent bone loss associated with cancer treatment.
- Integrate the above assessments into practice of cancer patient counseling, assessment and management.
Educational Need
Medical professionals who assess, treat and/or counsel cancer patients need to be able to assess and discuss new clinical data and recommendations related to the use of bone-targeted therapies to treat and prevent bone metastasis and prevent bone loss related to cancer treatment, and integrate this information into their own practice.
Faculty
Robert E. Coleman, MD, FRCP
Cancer Research Centre, Weston Park Hospital, Sheffield, UK
Theresa A. Guise, MD
Professor of Medicine Indiana University School of Medicine, Indianapolis, IN
Ingunn Holen, BSc, MSc, PhD
University of Sheffield Medical School, Sheffield, UK
Allan Lipton, MD
Professor of Medicine and Oncology, Penn State University, Hershey, PA
G. David Roodman, MD, PhD
VA Pittsburgh Healthcare System, Pittsburgh, PA
Sponsor
This activity is sponsoredby InforMEDical Communications, Inc., an independent medical education company providing up-to-date medical information to healthcare professionals who care for patients with cancer.
Accreditation
This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) by InforMEDical Communications, Inc. InforMEDical is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality and scientific integrity of this CME activity.
Educational Grant Support
Supported by educational grants provided by Amgen, Inc. and Novartis Pharmaceuticals.
Credit Designation
InforMEDical designates this continuing medical education activity for up to 3 AMA PRA Category 1 Credits™ . Participants should only claim credit commensurate with the extent of their participation in the activity.
Financial Disclosure
Authors: Robert Coleman, MD: Consultant for Amgen, Novartis,Pfizer, Roche; Expert testimony for Novartis; Honoraria from Amgen, Novartis, Pfizer, Roche; Research funding from AstraZeneca, Novartis; Speakers’ Bureau for Amgen, Novartis. Theresa Guise, MD: Consultant for Amgen; Research funding from Scios; Speakers’ Bureau for Amgen, Merck, Novartis. Ingunn Holen, BSc, MSc, PhD: Honoraria from Novartis; Research funding from Novartis, Galapagos; Speakers’ Bureau for Novartis. Allan Lipton, MD: Consultant for Amgen, Novartis; Expert testimony for Novartis; Honoraria from Amgen, Novartis; Research funding from Novartis; Speakers’ Bureau for Amgen, Novartis. G. David Roodman, MD, PhD: Consultant for Acceleron, Amgen, Celgene, Novartis; Research funding from Novartis; Speakers’ Bureau for Novartis. Peer Review: Larissa Korde MD, PhD: Nothing to disclose. Joel Neal, MD, PhD: Nothing to disclose. InforMEDical Program Managers and Editors: Nothing to disclose.
Disclaimer
This educational activity may contain discussion of published and/or investigational uses of agents, devices or diagnostics tools that have not been approved for use by the US FDA. The opinions expressed in the activity are those of the authors, and do not reflect those of the industry supporters or CME sponsor. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Participants/readers should appraise the information presented critically and are encouraged to consult appropriate resources for any product, device or diagnostic tool mentioned in this activity.